Researchers have found many ideal drugs to treat diseases of the central nervous system, but at the end they are being discarded. This is because these drugs are not able to cross the blood brain barrier that protects the brain. As a consequence the concern of creating a molecule able to cross the cellular barrier and transport the molecules to the brain arose. This triggered the creation of a "vehicle" built from amino acids. They are the building blocks of proteins which confer to the cell structure the transportation and storage of nutrients. With this innovation that was created from amino acids, it is expected to facilitate the treatment of brain diseases which they have not yet been able to find the cellular barrier that hinders the introduction of molecules to the brain.
A team of chemists at IRB Barcelona developed the small peptide with 12 amino acids "vehicle". Along with other researchers, they are looking for a more aggressive treatment for brain cancer in adults (glioblastoma), an inherited neurodegenerative disease (Friedreich's ataxia) and soon they will work for a type of childhood brain cancer. This "vehicle" has the advantage of lasting a period of 12-24 hours in the blood, it does not cause the immune system response and its toxicity is low. The leader of this research, Meritxell Teixidó says that 20% of humanity will need at some point in their lives a treatment directed to the brain. This major project would also lead to many pharmaceutical industries to "fish" efficient molecules to feed into the "vehicle" of amino acids to treat a brain disease.
 |
| Amino acids in a primary protein structure. |
This innovation has been patented by the authors of this "vehicle", to ensure possible future developments with this application ... With this innovation it is clear that every day new doors open for treatment of countless diseases that have failed to be confronted. The support they give each other as institutions is helping the daily advances, as this is an essential part of a job for everyone.
Credits:
Images:
No comments:
Post a Comment